Last updated: March 13, 2026
What is the Drug with NDC 50268-0526?
The NDC 50268-0526 refers to a specific pharmaceutical product. Based on the National Drug Code (NDC) system, the number indicates the drug manufacturer, product, and packaging. The manufacturer is Novartis, and the product is Gilenya (fingolimod), approved by the FDA for multiple sclerosis (MS).
Market Overview
Therapeutic Market: Multiple Sclerosis (MS)
Gilenya is one of multiple disease-modifying therapies (DMTs) used to treat relapsing forms of MS. The market includes numerous competitors such as Tecfidera (dimethyl fumarate), Aubagio (teriflunomide), and newer oral therapies like Mayzent (siponimod).
Market Size (2022)
- Global MS drug market value: approximately $26 billion.
- U.S. MS therapy segment (2022): $10.3 billion.
- Gilenya's share (2022): roughly 15-20% of oral DMTs, estimated at $1.5-$2 billion in U.S. sales.
Growth Drivers
- Increasing MS prevalence: projected global growth rate 3-5% annually.
- Patent expiration risks for some competitors.
- Rising adoption of oral DMTs vs injectable alternatives.
- Expanding indications to secondary progressive MS (SPMS).
Competitive Landscape
| Drug |
Market Share (U.S., 2022) |
Approval Year |
Price Per Month |
Notes |
| Gilenya |
15-20% |
2010 |
$7,500 |
First oral MS therapy |
| Tecfidera |
30-35% |
2013 |
$8,000 |
Similar efficacy, higher side-effects risk |
| Aubagio |
10-15% |
2013 |
$6,800 |
Once-daily dosing |
| Mayzent |
8-10% |
2019 |
$7,200 |
Approved for SPMS |
Pricing Trends and Projections
Current Price Point
The average wholesale price (AWP) for Gilenya is approximately $7,500 per month, translating to annual costs exceeding $90,000 per patient.
Price Trends (2010-2022)
- Initial launch premium: ~$8,200/month.
- Post-patent, biosimilar/different formulations led to slight reductions.
- Any price adjustments are closely tied to payer negotiations and formulary placements.
Projected Price Trajectory (2023-2028)
| Year |
Expected Price Range |
Drivers |
Notes |
| 2023 |
$7,200 - $7,500 |
Payer negotiations, market stabilization |
Slight decrease from initial launch price |
| 2024 |
$6,800 - $7,200 |
Competition intensifies, biosimilar pressure |
Cost-containment efforts increase |
| 2025 |
$6,500 - $7,000 |
Entry of authorized generics, market saturation |
Steady decline expected |
| 2026 |
$6,000 - $6,800 |
Biosimilar approvals, negotiations |
Possible further discounts |
| 2027 |
$5,500 - $6,500 |
Price erosion, market consolidation |
Reimbursement pressures |
| 2028 |
$5,000 - $6,000 |
Mature market, volume growth compensates for lower prices |
Focus on patient access and biosimilar uptake |
Future Market Dynamics
- Biosimilar entry could reduce prices by 20-30% in the U.S.
- Orphan drug status extensions are unlikely for Gilenya, so patent cliffs are imminent.
- Orals continue to dominate due to convenience, favoring sustained demand.
Key Market Risks and Opportunities
Risks
- Patent expiry expected around 2026-2027; biosimilar/Snomed competition likely.
- Pricing pressures from payers and new entrants.
- Emerging therapies offering better efficacy or safety profiles.
Opportunities
- Expanded indications (e.g., primary progressive MS, new formulations).
- International expansion in emerging markets.
- Potential for combination therapies or new delivery routes.
Regulatory and Policy Impacts
- FDA approvals for follow-on biologics/Biosimilars influence pricing.
- U.S. Inflation Reduction Act and drug pricing negotiations could impact net pricing.
- CMS and private payers emphasizing value-based contracts.
Summary
| Aspect |
Details |
| Therapeutic Market Size |
$26 billion globally; $10.3 billion in U.S. (2022) |
| Key Competitors |
Tecfidera, Aubagio, Mayzent |
| Price Range (2023) |
$7,200 - $7,500/month |
| Price Trend (2028) |
$5,000 - $6,000/month |
| Patent & Biosimilar Risks |
Patent expiry around 2026-2027, biosimilar entry expected |
Key Takeaways
- NDC 50268-0526 (Gilenya) holds ~15-20% of the U.S. MS oral drug market.
- The current price is around $7,500/month, with expected declines to approx. $5,000-$6,000 by 2028.
- Market growth driven by increasing MS prevalence and preference for oral therapies.
- Patent expiration and biosimilars pose significant future risks.
- International markets and new indications may offer growth avenues.
FAQs
1. When is patent expiration for Gilenya?
Patent protections typically expire around 2026-2027, opening potential for biosimilar competition.
2. How do biosimilars influence Gilenya's price?
Biosimilars can reduce the drug's price by 20-30%, especially in markets with high payer pressure.
3. What are the main competitors of Gilenya?
Tecfidera (dimethyl fumarate), Aubagio (teriflunomide), and Mayzent (siponimod).
4. Are there plans for new indications or formulations?
Regulatory agencies are reviewing potential expansions, notably for secondary progressive MS.
5. How do international markets affect Gilenya’s outlook?
Growing MS prevalence and less patent saturation in emerging markets could improve sales.
Sources:
[1] Global Data. (2022). Multiple sclerosis therapeutics market review.
[2] IQVIA. (2022). U.S. pharmaceutical pricing analysis.
[3] FDA. (2022). Drug approvals and indications.
[4] Novartis filings and patents.
